Roy F. Waldron
Directeur/Bestuurslid bij Starton Therapeutics, Inc.
Actieve functies van Roy F. Waldron
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Starton Therapeutics, Inc.
 Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | Directeur/Bestuurslid | 01-05-2019 | - |
Loopbaan van Roy F. Waldron
Eerdere bekende functies van Roy F. Waldron
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | - | - |
Opleiding van Roy F. Waldron
| New York University School of Law | Graduate Degree |
| Yale University | Doctorate Degree |
| Dartmouth College | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 6 |
Operationeel
| Director/Board Member | 2 |
| Independent Dir/Board Member | 1 |
| Corporate Officer/Principal | 1 |
Sectoraal
| Consumer Services | 4 |
| Health Technology | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | Health Technology |
- Beurs
- Insiders
- Roy F. Waldron
- Ervaring